Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhai, Zhimin
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)	Recruiting	2	150	RoW	AZD4205	Dizal Pharmaceuticals	Peripheral T Cell Lymphoma	05/25	12/26
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma	Recruiting	2	185	RoW	HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor	Hutchison Medipharma Limited	Marginal Zone Lymphoma, Follicular Lymphoma	04/24	12/24
EECNTL, NCT02735291: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia	Active, not recruiting	N/A	72	RoW	CD19-targeted CAR-T cells	Sinobioway Cell Therapy Co., Ltd., The Second Hospital of Anhui Medical University	Leukemia	12/19	12/25